What to Expect When Navigating the Emergency Room (E.R.) with an Inhibitor?
Prepare for Emergency Room visits with inhibitors by advocating for yourself and utilizing MASAC for You's comprehensive guidelines.
Can an Inhibitor be Removed?
Explore the possibilities of this proactive treatment, Immune Tolerance Therapy (ITI) for inhibitor removal.
How do I prevent and treat bleeds when I have an Inhibitor?
Explore effective treatment options for individuals with inhibitors, navigating the complexities with insights into the three main types of interventions. Find comprehensive solutions tailored to your unique needs.
How can I tell if I have developed an inhibitor?
Discover the subtle signs of inhibitor development in individuals, including increased dependence on higher doses of factor replacement products.
Avances en el Tratamiento
Son tiempos emocionantes en la investigación de los trastornos hemorrágicos, con nuevas opciones de tratamiento en el horizonte.
Technologies and Advancements in Inhibitor Treatments
Treating hemophilia with an inhibitor is never a one-size-fits-all situation. During this session, experts will discuss past, current, and future advancement options for treating hemophilia with inhibitors along with hot research topics.
New Data Shows Eptacog Beta Safe and Effective in Pediatric Patients
New Data Shows Eptacog Beta Safe and Effective in Pediatric Patients
Newly published data from a phase 3 clinical study suggests that the recombinant factor VIIa bypassing agent (BPA) eptacog beta was used to safely and effectively treat and control bleeding in children with hemophilia A or B with inhibitors, 12 years of age or younger.
Inhibitor Treatments: Now and the Future
NBDF provides free quality education on issues that matter to the bleeding disorders community. This video is on inhibitor treatments: now and the future
When the Immune System Attacks!
NBDF provides free quality education on issues that matter to the bleeding disorders community. This video is about when the immune system attacks
Pain Impact: The Psychosocial Lens
Pain plays a substantial role in many people’s lives, including those with bleeding disorders. This session unpacks the impact of psychosocial aspects on the experience of pain and how addressing these can benefit the whole person.
Joint Connections: Pain Management and Joint Health
During this session, a panel of community members shares their experiences with pain management and joint health. The panel discusses pain management techniques and therapies and more
What is an Inhibitor?
Learn about hemophilia inhibitors, an immune response that affects clotting factor treatment. Explore how inhibitors develop and impact bleeding disorders.
El Costo de la Reentrada
Después de un año difícil impulsado por la pandemia de COVID19, esperamos una nueva normalidad. Pero, ¿cómo afecta la reincorporación
Pregunte a los expertos
¿Tiene una pregunta candente que hacerle a nuestro panel de expertos? Esta sesión ofrecerá a los participantes la oportunidad de interactuar, participar y hacer preguntas que inviten a la reflexión a un panel de proveedores de atención médica interdisciplinarios en tiempo real. Esta discusión incluirá Miguel Escobar, MD; Kelli Fraga, PT, DPT; Sabrina Farina, LMSW
Inhibitor Education Series: Baby Steps Navigating Past the Pandemic
Re-entering society after the COVID19 pandemic, how does it impact mental health, and what are specific implications for the bleeding disorder community?
Inhibitor Education Series: Ask the Experts
This session will offer participants an opportunity to interact, engage, and ask thought-provoking questions to a panel of interdisciplinary healthcare providers in real time.
FDA Places Clinical Hold on Sigilon’s Investigational Hemophilia Therapy
FDA Places Clinical Hold on Sigilon’s Investigational Hemophilia Therapy
Sigilon's cell-based therapy is designed to carry significant amounts of synthetic DNA material to elicit the production of factor VIII in individuals with hemophilia A.
New Inhibitor Study Using MLOF Research Repository Data Published
New Inhibitor Study Using MLOF Research Repository Data Published
The study represents a significant step toward better understanding of inhibitors and improving clinical care.
What Everyone Who Treats with Factor Needs To Know About Inhibitors
If you treat with clotting factor, you may be at risk of developing an inhibitor. This workshop is for people who do not have an inhibitor but want to learn more about risk. We will explain the basics of inhibitors, how they develop, and how and why you should have a conversation with your healthcare provider about screening and monitoring for an inhibitor.
De lo que todos los que tratan con factor sobre los Inhibidores
Si trata con factor de coagulación, puede estar en riesgo de desarrollar un inhibidor. Este taller es para personas que no tienen un inhibidor pero desean aprender más sobre el riesgo.
Spark Announces Preliminary Data from Investigational Gene Therapy Trial
Spark Announces Preliminary Data from Investigational Gene Therapy Trial
The first part of this phase 1/2 trial is designed to evaluate the safety and efficacy of SPK-8016 in adult males with clinically severe hemophilia A and no measurable inhibitor against FVIII.
Octapharma Announces Final Results of Nuwiq® Study
Octapharma Announces Final Results of Nuwiq® Study
Nuwiq® is indicated for on-demand treatment and control of bleeding episodes and routine prophylaxis to reduce the frequency of bleeding episodes and perioperative management of bleeding.
BioMarin Announces Positive Phase 3 Study Data for Valoctocogene Roxaparvovec
BioMarin Announces Positive Phase 3 Study Data for Valoctocogene Roxaparvovec
The phase 3 trial currently includes 134 participants with hemophilia A, all of whom have received a single dose of the gene therapy.
Learning to Let Go: Fostering Independence
As parents of teens with hemophilia and an inhibitor, one of those biggest challenges, preparing to let go, can be especially difficult.
Communicating with Your Provider About Pain
This session will improve understanding of how pain affects people with bleeding disorders and will offer guidelines for managing acute and chronic pain.
What about Research?
Explore the latest research efforts to understand the development of hemophilia inhibitors. Stay informed about genetic insights, immunology & ongoing studies.
Social and Financial Considerations
Learn how to manage the costs and emotional challenges of inhibitor treatment. Get guidance on financial assistance and social support at NBDF.
How Do I Get Tested for an Inhibitor?
Learn how to get tested for an inhibitor in bleeding disorders, understand the Bethesda assay, and discover the different types of inhibitors. Get the facts.
Can I Develop an Inhibitor?
Explore the factors contributing to inhibitor development in patients with bleeding disorders, affecting their response to clotting factor treatment.
Inhibitors
Learn about inhibitors, a complication in bleeding disorders where the immune system reacts to clotting factor treatments. Explore diagnosis and management.
Inhibitor Education
Explore resources and support for families living with hemophilia inhibitors. Learn about educational events, publications, webinars, and more.
Three Concizumab Trials Halted by Novo Nordisk
Three Concizumab Trials Halted by Novo Nordisk
The halted trials were investigating concizumab prophylaxis treatment in hemophilia A and B patients regardless of inhibitor status.
CDC Hosts Inhibitor Testing Webinar
CDC Hosts Inhibitor Testing Webinar
Join the CDC Inhibitor Testing Webinar on Thursday, July 24, at 2PM EST, to find out more about this complication.